CDEC final recommendation: Dolutegravir (Tivicay -- ViiV Healthcare ULC) indication : HIV infection
The Canadian Drug Expert Committee (CDEC) recommends that dolutegravir be listed for the treatment of HIV in both treatment-naive and treatment-experienced adults and children 12 years of age and older weighing at least 40 kg
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
August 18, 2014, 2014
|
Series: | Common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The Canadian Drug Expert Committee (CDEC) recommends that dolutegravir be listed for the treatment of HIV in both treatment-naive and treatment-experienced adults and children 12 years of age and older weighing at least 40 kg |
---|---|
Physical Description: | 1 PDF file (7 pages) |